Klonopin Wafer Side Effects

Generic Name: clonazepam

Please note - some side effects for Klonopin Wafer may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

Side Effects of Klonopin Wafer - for the Consumer

Klonopin Wafer Orally Disintegrating Tablets

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Klonopin Wafer Orally Disintegrating Tablets:

Clumsiness or unsteadiness; constipation; cough; dizziness; drowsiness; dry mouth; headache; increased saliva production; lightheadedness; loss of appetite; muscle aches; nervousness; runny nose; tiredness.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); behavior changes; blurred vision or other vision changes; change in the amount of urine produced; confusion; dark urine; fever, chills, or sore throat; hallucinations; hostility; irregular heartbeat; memory loss or problems; mental or mood changes (eg, agitation, aggression, anxiety; depression, hostility, irritability); new or worsening seizures; painful menstrual periods; painful urination; severe drowsiness; severe or persistent tiredness or weakness; shortness of breath; slow or shallow breathing; slurred speech or other speech problems; suicidal thoughts or actions; tremor; unusual bruising or bleeding; yellowing of the skin or eyes.

Side Effects by Body System

Nervous system

Nervous system side effects are common, particularly at the initiation of therapy and include drowsiness, fatigue, ataxia, confusion, depression, daytime anxiety, and amnesia. Nystagmus, diplopia, vertigo, headache, respiratory depression, tremor and slurred speech have also been reported less frequently.

Sedation may initially occur in up to 50% of treated patients. Ataxia may occur in 30% of patients. Five to 6% of patients treated with clonazepam for seizures may develop more frequent seizures or a new type of seizure disorder. Weakness and hypotonia have also been reported. A case report has suggested that clonazepam may induce Tourette's syndrome.

Psychiatric

Behavioral problems have been reported in as many as 30% of treated patients.

Psychiatric side effects have been reported and include behavioral disinhibition (particularly sexual disinhibition), depression, and rarely, psychosis and mania.

Other

Other side effects have included withdrawal symptoms (similar to those which may occur after withdrawal of barbiturates and alcohol) which have been reported after abrupt cessation of clonazepam. Specifically, seizures, agitation, restlessness, anxiety, delirium, psychosis, dysphoria, insomnia, tremor, abdominal cramps, vomiting, rash, and sweating have been reported to have occurred, especially after long-term therapy.

Genitourinary

In one study, anorgasmia occurred in 44% of patients treated with clonazepam while anorgasmia occurred in only 6% of patients treated with placebo.

Genitourinary side effects may include urinary incontinence, anorgasmia, ejaculatory delay, and erectile dysfunction.

Hematologic

Hematologic side effects including thrombocytopenia have been reported rarely.

Gastrointestinal

Gastrointestinal side effects including hypersalivation, diarrhea, constipation, nausea, increased appetite, and anorexia have been reported.

Respiratory

Respiratory side effects including bronchial hypersecretion have been reported.

Dermatologic

Dermatologic side effects have included cases of rashes associated with clonazepam therapy. A case of erythema multiforme associated with clonazepam therapy has also been reported.

Ocular

Clonazepam is contraindicated in patients with narrow angle glaucoma.

Ocular side effects including acute worsening of narrow angle glaucoma is possible with clonazepam therapy.

Metabolic

Metabolic side effects have included exacerbation of seizure disorders in some patients with acute intermittent porphyria. However, a case report has suggested that clonazepam may be beneficial in this setting as well.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.